Publication at First Faculty of Medicine |
2023
Abstract
Sacituzumab govitecan is a new therapeutic option in triple negative breast cancer treatment. Sacituzumab govitecan is an antibody-drug conjugate.
The antibody targets the Trop-2 antigen and is coupled to small molecules of SN-38. SN-38 inhibits topoisomerase I after hydrolysis of the linker.
It leads to DNA damage, apoptosis and cell death. The registration in the metastatic triple-negative breast cancer treatment is based on data from ASCENT trial.
Progression-free and overall survival were longer with sacituzumab govitecan in second line of the treatment, or higher line, than with chemotherapy. In the Czech Republic, it is not yet paid from public health insurance.